July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Identification of a retinal neuroprotective kinase inhibitor with preferential activity against DLK compared to LZK
Author Affiliations & Notes
  • Derek Stuart Welsbie
    Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
    Wilmer Ophthalmological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Hartmut Schirok
    Bayer AG Pharmaceuticals, Wuppertal, Germany
  • Katherine Mitchell
    Wilmer Ophthalmological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Michael Koch
    Bayer AG Pharmaceuticals, Wuppertal, Germany
  • Byung-Jin Kim
    Wilmer Ophthalmological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Mario Lobell
    Bayer AG Pharmaceuticals, Wuppertal, Germany
  • Amit K Patel
    Shiley Eye Institute, University of California San Diego, La Jolla, California, United States
  • Simon Holton
    Bayer AG Pharmaceuticals, Berlin, Germany
  • Dmitrij Hristodorov
    Bayer AG Pharmaceuticals, Berlin, Germany
  • Julian Esteve-Rudd
    Bayer AG Pharmaceuticals, Wuppertal, Germany
  • Cynthia Berlinicke
    Wilmer Ophthalmological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Carsten Terjung
    Bayer AG Pharmaceuticals, Wuppertal, Germany
  • Baranda S. Hansen
    Wilmer Ophthalmological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Nicolas Werbeck
    Bayer AG Pharmaceuticals, Berlin, Germany
  • William Schubert
    Bayer AG Pharmaceuticals, Wuppertal, Germany
  • Donald J Zack
    Wilmer Ophthalmological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Derek Welsbie, Bayer Pharmaceuticals AG (F); Hartmut Schirok, Bayer Pharmaceuticals AG (E); Katherine Mitchell, Bayer Pharmaceuticals AG (F); Michael Koch, Bayer Pharmaceuticals AG (E); Byung-Jin Kim, Bayer Pharmaceuticals AG (F); Mario Lobell, Bayer Pharmaceuticals AG (E); Amit Patel, Bayer Pharmaceuticals AG (F); Simon Holton, Bayer Pharmaceuticals AG (E); Dmitrij Hristodorov, Bayer Pharmaceuticals AG (E); Julian Esteve-Rudd, Bayer Pharmaceuticals AG (E); Cynthia Berlinicke, Bayer Pharmaceuticals AG (F); Carsten Terjung, Bayer Pharmaceuticals AG (E); Baranda Hansen, Bayer Pharmaceuticals AG (F); Nicolas Werbeck, Bayer Pharmaceuticals AG (E); William Schubert, Bayer Pharmaceuticals AG (E); Donald Zack, Bayer Pharmaceuticals AG (F)
  • Footnotes
    Support  Bayer
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2493. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Derek Stuart Welsbie, Hartmut Schirok, Katherine Mitchell, Michael Koch, Byung-Jin Kim, Mario Lobell, Amit K Patel, Simon Holton, Dmitrij Hristodorov, Julian Esteve-Rudd, Cynthia Berlinicke, Carsten Terjung, Baranda S. Hansen, Nicolas Werbeck, William Schubert, Donald J Zack; Identification of a retinal neuroprotective kinase inhibitor with preferential activity against DLK compared to LZK. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2493.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Dual leucine zipper kinase (DLK, MAP3K12) signaling has been implicated in the death of multiple types of neurons, and inhibitors of DLK promote retinal neuronal survival in a variety of in vitro and in vivo models. Additionally, the homologous protein leucine zipper kinase (LZK, MAP3K13) acts synergistically in inducing retinal ganglion cell (RGC) death. With the goal of developing novel therapeutics for retinal disease, we have been working to develop highly-specific small molecule DLK inhibitors.

Methods : A TR-FRET based high throughput assay was developed and used to assay nearly four million compounds for DLK inhibitory activity. Dissociation constants were determined for selected “hits” using an SPR binding assay. Broader kinase selectivity profiles were assessed (Eurofins). Neuroprotective activity was assessed by measuring the survival of primary mouse RGCs. Medicinal chemistry was used to optimize lead compounds.

Results : The diazepinone BAY-452 inhibits DLK in our biochemical assay, IC50 = 180 nM; similar KD values were determined at DiscoverX (KD = 88 nM) and in an SPR assay (KD = 110 nM). Unlike most other DLK inhibitors, whose LZK inhibitory activity tends to parallel their activity against DLK, BAY-452 is markedly less active against LZK, demonstrating an IC50 of approximately 9 µM. Based upon a co-crystal structure of BAY-452 with DLK’s kinase domain, we developed a hypothesis to explain its preference for DLK over LZK. BAY-452 is only moderately selective – in a test panel of 318 kinases, 50 were inhibited >70% at 1 µM compound concentration. BAY-452 shows mixed PK in vitro, with good permeation in a Caco2 assay, but only intermediate-to-low metabolic stability in rat hepatocytes. Consistent with these results, in an initial PK study in mice, the half-life is 0.76 hr. BAY-452 promotes the survival of RGCs, but with considerably less potency than other molecules with similar DLK and greater LZK inhibitory activity. Genetic disruption of LZK increases BAY-452’s RGC survival promoting activity.

Conclusions : Through a combination of high throughput screening and medicinal chemistry we identified the diazepinone BAY-452 as a potent DLK inhibitor. Compared to other DLK inhibitors, BAY-452 shows selectivity against DLK vs. LZK. Thus BAY-452 may serve as a useful molecular probe to dissect the role of DLZ vs. LZK activity in cellular signaling and neuroprotection.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×